In 2023, the import value of cortisone, hydrocortisone, prednisone, and prednisolone to Germany stood at approximately 12.7 million US dollars. The forecast from 2024 to 2028 indicates a gradual decline in import value, decreasing from 12.538 million USD in 2024 to 11.978 million USD in 2028. This presents a year-on-year decrease of approximately 1.2% per annum.
The compound annual growth rate (CAGR) over the forecasted period reflects a declining average of approximately 1.1% per year. This steady downward trend suggests a shrinking demand or an increase in domestic production capabilities for these compounds in Germany. The market dynamics, such as regulatory changes and advancements in alternative therapies, will be vital to monitor. Other factors like innovations in pharmaceutical replacement therapies and the evolving landscape of global trade agreements could also significantly influence future trends.
